Sayed M.S. Hashemi

2.2k total citations
57 papers, 1.1k citations indexed

About

Sayed M.S. Hashemi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sayed M.S. Hashemi has authored 57 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sayed M.S. Hashemi's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Colorectal Cancer Treatments and Studies (13 papers). Sayed M.S. Hashemi is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Diagnosis and Treatment (20 papers) and Colorectal Cancer Treatments and Studies (13 papers). Sayed M.S. Hashemi collaborates with scholars based in Netherlands, United States and United Kingdom. Sayed M.S. Hashemi's co-authors include Egbert F. Smit, Adrianus J. de Langen, Suresh Senan, Kim Monkhorst, Max Dahele, Ben J. Slotman, Erik Thunnissen, Daniëlle A.M. Heideman, Teodora Radonic and F. Spoelstra and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Sayed M.S. Hashemi

55 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sayed M.S. Hashemi Netherlands	16	873	560	211	158	144	57	1.1k
Vasu Tumati United States	13	839 1.0×	455 0.8×	155 0.7×	202 1.3×	296 2.1×	27	1.2k
Libor Havel Czechia	21	980 1.1×	1.2k 2.2×	249 1.2×	81 0.5×	83 0.6×	54	1.6k
Cheng‐Bo Han China	17	471 0.5×	381 0.7×	270 1.3×	112 0.7×	77 0.5×	76	864
Youling Gong China	21	662 0.8×	534 1.0×	439 2.1×	240 1.5×	251 1.7×	89	1.4k
John M. Varlotto United States	21	754 0.9×	433 0.8×	163 0.8×	183 1.2×	79 0.5×	54	1.3k
Michael S. Binkley United States	12	378 0.4×	202 0.4×	86 0.4×	159 1.0×	187 1.3×	45	688
Jie‐Tao Ma China	15	364 0.4×	311 0.6×	198 0.9×	96 0.6×	54 0.4×	43	677
Vanessa Bolejack United States	11	1.1k 1.3×	600 1.1×	270 1.3×	340 2.2×	27 0.2×	16	1.5k
Mai Trong Khoa Vietnam	11	1.2k 1.3×	810 1.4×	276 1.3×	93 0.6×	30 0.2×	27	1.3k
Lars Stenbygaard Denmark	12	305 0.3×	657 1.2×	240 1.1×	142 0.9×	177 1.2×	29	1.1k

Countries citing papers authored by Sayed M.S. Hashemi

Since Specialization

Citations

This map shows the geographic impact of Sayed M.S. Hashemi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sayed M.S. Hashemi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sayed M.S. Hashemi more than expected).

Fields of papers citing papers by Sayed M.S. Hashemi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sayed M.S. Hashemi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sayed M.S. Hashemi. The network helps show where Sayed M.S. Hashemi may publish in the future.

Co-authorship network of co-authors of Sayed M.S. Hashemi

This figure shows the co-authorship network connecting the top 25 collaborators of Sayed M.S. Hashemi. A scholar is included among the top collaborators of Sayed M.S. Hashemi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sayed M.S. Hashemi. Sayed M.S. Hashemi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hashemi, Sayed M.S., et al.. (2025). Evaluating the significance of combining PD-L1 and TILs as biomarkers in non-small cell lung cancer patients treated with immunotherapy: a systematic review. PubMed. 3(1). 65–65.

Cheng, Ying, David R. Spigel, Jian Fang, et al.. (2024). MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC. Journal of Thoracic Oncology. 19(10). S124–S125. 1 indexed citations

Zeverijn, Laurien J., Birgit S. Geurts, Gijs F. de Wit, et al.. (2024). Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol. Clinical Cancer Research. 30(23). 5323–5332. 1 indexed citations

Bahce, Idris, Chris Dickhoff, Famke L. Schneiders, et al.. (2024). Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study. Journal for ImmunoTherapy of Cancer. 12(9). e009799–e009799. 5 indexed citations

Hashemi, Sayed M.S., Marc C. Huisman, Daniela E. Oprea‐Lager, et al.. (2024). First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET. Journal for ImmunoTherapy of Cancer. 12(2). e007659–e007659. 3 indexed citations

Wekken, Anthonie J. van der, Marthe S. Paats, Lizza Hendriks, et al.. (2023). A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer. Cancer. 130(5). 683–691. 4 indexed citations

Verkerk, Karin, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2023). 1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP). Annals of Oncology. 34. S797–S798. 3 indexed citations

Langen, Adrianus J. de, Kim Monkhorst, Mirjam C. Boelens, et al.. (2023). Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC. JTO Clinical and Research Reports. 4(4). 100481–100481. 19 indexed citations

Hashemi, Sayed M.S., Ilias Houda, Joris D. Veltman, et al.. (2023). Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC. JTO Clinical and Research Reports. 4(9). 100532–100532. 24 indexed citations

10.

Zhang, Zhen, Anne‐Marie C. Dingemans, Joachim G.J.V. Aerts, et al.. (2023). Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors. European Journal of Cancer. 183. 142–151. 16 indexed citations

11.

Heineman, David J., Famke L. Schneiders, Ilias Houda, et al.. (2023). OA06.04 Surgery after Neoadjuvant Immuno-Chemoradiotherapy in (Borderline) Resectable NSCLC: Results from the INCREASE Trial. Journal of Thoracic Oncology. 18(11). S56–S57. 4 indexed citations

12.

Houda, Ilias, Sayed M.S. Hashemi, Johannes M. A. Daniels, et al.. (2023). 1445P A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis. Annals of Oncology. 34. S821–S822. 1 indexed citations

13.

Ünal, Serhat, David J. Heineman, Idris Bahce, et al.. (2023). Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors. JTO Clinical and Research Reports. 4(4). 100475–100475. 7 indexed citations

14.

Bahce, Idris, Famke L. Schneiders, Sayed M.S. Hashemi, et al.. (2022). 1020P Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study. Annals of Oncology. 33. S1021–S1021. 1 indexed citations

15.

Dickhoff, Chris, Idris Bahce, Anton F. Engelsman, et al.. (2022). Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period. Radiotherapy and Oncology. 170. 165–168. 9 indexed citations

16.

Hashemi, Sayed M.S., Marieke F. Fransen, Anna-Larissa N. Niemeijer, et al.. (2021). Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer. 153. 81–89. 49 indexed citations

17.

Bahce, Idris, Sayed M.S. Hashemi, Chris Dickhoff, et al.. (2020). Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. Lung Cancer. 152. 149–156. 10 indexed citations

18.

Hashemi, Sayed M.S., Marthe S. Paats, Kim Monkhorst, et al.. (2019). Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer. 141. 9–13. 60 indexed citations

19.

Langen, Adrianus J. de, Sayed M.S. Hashemi, Kim Monkhorst, et al.. (2018). Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC. Journal of Thoracic Oncology. 13(8). 1222–1226. 55 indexed citations

20.

Kuiper, JG, Sayed M.S. Hashemi, Erik Thunnissen, et al.. (2016). Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. British Journal of Cancer. 115(12). 1504–1512. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact